IN8bio (INAB) Competitors $2.24 -0.03 (-1.11%) As of 09:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INAB vs. PYRGF, LVTX, MDCX, CALC, MRSN, XCUR, OKUR, RVPH, XLO, and MURAShould you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include PyroGenesis Canada (PYRGF), LAVA Therapeutics (LVTX), Medicus Pharma (MDCX), CalciMedica (CALC), Mersana Therapeutics (MRSN), Exicure (XCUR), OnKure Therapeutics (OKUR), Reviva Pharmaceuticals (RVPH), Xilio Therapeutics (XLO), and Mural Oncology (MURA). These companies are all part of the "pharmaceutical products" industry. IN8bio vs. Its Competitors PyroGenesis Canada LAVA Therapeutics Medicus Pharma CalciMedica Mersana Therapeutics Exicure OnKure Therapeutics Reviva Pharmaceuticals Xilio Therapeutics Mural Oncology IN8bio (NASDAQ:INAB) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability. Do analysts rate INAB or PYRGF? IN8bio currently has a consensus price target of $180.00, suggesting a potential upside of 7,953.69%. Given IN8bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe IN8bio is more favorable than PyroGenesis Canada.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, INAB or PYRGF? IN8bio has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Does the media refer more to INAB or PYRGF? In the previous week, IN8bio had 1 more articles in the media than PyroGenesis Canada. MarketBeat recorded 1 mentions for IN8bio and 0 mentions for PyroGenesis Canada. IN8bio's average media sentiment score of 1.88 beat PyroGenesis Canada's score of 0.00 indicating that IN8bio is being referred to more favorably in the media. Company Overall Sentiment IN8bio Very Positive PyroGenesis Canada Neutral Do insiders & institutionals believe in INAB or PYRGF? 92.1% of IN8bio shares are held by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are held by institutional investors. 15.5% of IN8bio shares are held by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is INAB or PYRGF more profitable? IN8bio has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat IN8bio's return on equity.Company Net Margins Return on Equity Return on Assets IN8bioN/A -184.97% -126.75% PyroGenesis Canada -115.14%N/A -60.81% Which has higher earnings & valuation, INAB or PYRGF? PyroGenesis Canada has higher revenue and earnings than IN8bio. PyroGenesis Canada is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIN8bioN/AN/A-$30.44M-$9.11-0.25PyroGenesis Canada$9.14M4.22-$21.12M-$0.03-6.86 SummaryIN8bio beats PyroGenesis Canada on 8 of the 15 factors compared between the two stocks. Get IN8bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INAB vs. The Competition Export to ExcelMetricIN8bioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.15M$3.10B$5.77B$9.79BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-0.2521.0831.2726.59Price / SalesN/A359.72440.26156.12Price / CashN/A44.6737.7359.36Price / Book0.678.0910.616.68Net Income-$30.44M-$54.08M$3.27B$265.59M7 Day Performance-1.11%-0.41%1.41%0.62%1 Month Performance1.59%6.23%6.20%2.61%1 Year Performance-85.65%10.45%50.13%22.34% IN8bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INABIN8bio3.9108 of 5 stars$2.24-1.1%$180.00+7,953.7%-85.7%$10.15MN/A-0.2520Positive NewsPYRGFPyroGenesis CanadaN/A$0.22-3.9%N/A-64.5%$40.38M$9.14M-3.5990LVTXLAVA Therapeutics2.4026 of 5 stars$1.51-1.3%$2.69+77.8%-12.9%$40.25M$11.98M-1.4460MDCXMedicus Pharma1.7432 of 5 stars$2.17-2.3%$23.50+982.9%N/A$39.55MN/A-1.62N/AGap UpCALCCalciMedica3.4724 of 5 stars$2.79+0.4%$16.00+473.5%-35.0%$38.84MN/A-1.7430Positive NewsMRSNMersana Therapeutics4.1613 of 5 stars$7.65-1.3%$56.60+639.9%-79.4%$38.68M$40.50M-0.52150XCURExicure2.021 of 5 stars$5.92-2.8%N/A+1,169.2%$38.47M$500K-1.5350Positive NewsGap UpOKUROnKure Therapeutics2.9089 of 5 stars$2.82-0.4%$32.33+1,046.6%N/A$38.29MN/A-0.59N/ATrending NewsAnalyst ForecastAnalyst RevisionGap DownRVPHReviva Pharmaceuticals2.6751 of 5 stars$0.52-4.3%$7.17+1,290.0%-54.4%$36.62MN/A-0.795XLOXilio Therapeutics3.2298 of 5 stars$0.70-0.4%$3.00+328.5%-14.8%$36.44M$6.34M-0.9270MURAMural Oncology2.7693 of 5 stars$2.06-1.0%$12.00+482.5%-34.3%$36.03MN/A-0.24119 Related Companies and Tools Related Companies PYRGF Competitors LVTX Competitors MDCX Competitors CALC Competitors MRSN Competitors XCUR Competitors OKUR Competitors RVPH Competitors XLO Competitors MURA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INAB) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IN8bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access